In response to the dynamic changes in the illicit drug landscape, this session aims to address the concerns of clinicians who prescribe buprenorphine, as they increasingly question their understanding of dosing in relation to the evolving street drug supply, especially with the rise of fentanyl, carfentanil, and contaminants like xylazine in our communities.

Alicia M Gonzalez, MD
Charles Hawthorne, MPH